E129: Sam Altman plays chess with regulators, AI's "nuclear" potential, big pharma bundling & more
All-In with Chamath, Jason, Sacks & Friedberg
00:00
Tech, Regulation, and Pharmaceutical Dynamics
This chapter explores the intersection of tech companies and regulatory narratives, particularly in the context of a new Twitter CEO amid political scrutiny. It further examines the complexities of the pharmaceutical industry, highlighting FTC concerns over an acquisition and how regulatory practices impact innovation and pricing. The discussion emphasizes the challenges posed by censorship in media and the evolving landscape of biotech financing in light of regulatory interventions.
Transcript
Play full episode
